|
|
 |
|
Viewing report
|
|
|
|
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
BioPharm Reports (VennBio Ltd.), July 2009, Pages: 188
With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.
Interventional treatments, such as peripheral nerve block and transcutaneous electrical nerve stimulation, are also used as physicians seek other approaches to treating NP. This background, the individual nature of NP and the drug (or drug combination) options used to treat patients, has created a complex therapeutic picture.
In a therapeutic field where treatments are often unsatisfactory, physicians seek to extent their understanding of NP in an effort to define needs and limitations. Knowledge in these areas is also important to drug developers, who seek a better understanding of patient needs and outcomes, as part of their own efforts to develop more effective therapies. To meet interest in these areas, Biopharm Reports has conducted an in-depth global survey on current treatments and drug prescribing practices, relating to NP. This survey involved the participation of more than 330 physicians and clinical centres in 56 countries.
Overview:
Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries
In-depth information relevant to markets and opportunities in the NP field.
98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment.
Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium.
74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin.
- Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients.
- Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP.
- Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available.
- A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS).
- An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions.
- Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP.
Information surveyed:
- Participant details: Participant organisation, type of clinical practice or department; type of pain physician
- NP treatment strategies: Relative proportion of drug and interventional treatments
- Diagnoses and underlying pathologies: For example, Diabetes, post cancer radiotherapy or chemotherapy, post general surgery, Trigeminal Neuralgia, viral Infections, injury/trauma, post back surgery, primary back problems, complex regional pain syndrome (CRPS), Multiple Sclerosis, central pain, Arthritis, Others NP pathologies
- Single or combined drug treatments
- Drug classes used: For example, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenalin reuptake inhibitors (SNRIs), anticonvulsants, sodium channel blockers, opioids, non-steroidal anti-inflammatory drugs, cannabinoids, Capsaicin and others
- Tricyclic Antidepressants: First, second and third most frequently used
- Non-steroidal anti-inflammatory drugs: First, second and third most frequently used
- Cannabinoids
- Capsaicin
- Drug combinations: First, second and third most frequently used drug combinations (i.e. combinations of two, three or more than three specific drug classes)
- Pain relief: Pain relief profile for the major underlying pathologies (levels of pain relief for each underlying pathology)
- Interventional treatments: use of interventional treatments such as epidural injections, facet joint injections, facet joint denervation, large joint injections, medical acupuncture, nerve root blocks, peripheral nerve blocks, prolotherapy, sympathetic blocks, lumbar sympathectomy, spinal manipulation, trigger point injections, tendon sheath/bursa injections, intrathecal injection, spinal chord stimulation, intramuscular stimulation, TENS and others.
- Clinical issues and challenges in the treatment of NP: Individual responses from physicians to this question
- Selective serotonin reuptake inhibitors: First, second and third most frequently used
- Any other comments on the treatment of Neuropathic Pain: Individual responses from physicians to this question
- Serotonin-noradrenalin reuptake inhibitors: First, second and third most frequently used
- Anticonvulsants: First, second and third most frequently used
- Sodium Channel Blockers: First, second and third most frequently used
- Opioids: First, second and third most frequently used
Customers who bought this item also bought
Peripheral Neuropathy and Neuropathic Pain
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail To Nail Neuropathic Pain
Pain Therapeutics - Drugs, Markets and Companies
US Neuropathic Pain 2008 - 4th Edition: Market Potential Through 2018
Stakeholder Insight: Diabetic Neuropathic Pain - Market Success is Not Limited to Pregabalin
Neuropathic Pain Insight - Life Beyond Gabapentin
Pipeline Insight: Neuropathic Pain - Emerging Drugs Fail to Capitalize in Lucrative Market
Stakeholder Insight: Neuropathic Pain - Comparative Overview of Treatment Preferences Across the Seven Major Markets
US Cancer Pain Report
U.S. Neuropathic Pain Medications Markets
Stakeholder Insight: HIV Related Neuropathic Pain - Useful Niche for Peripheral Companies
Back Pain Report 2008
|
|
|
|
